Loading...

TYRA TYRA BIOSCIENCES INC US FDA Inspections 8-K Filing

TYR

TYR

TYRA BIOSCIENCES INC

(TYRA)

2025 8-K

Management Change

Financial Results Announcement

Clinical Study Update

Financial Results Report

Product Expansion

Financial Statements

Financial Results

Financial Results

Director Resignation

Equity Exchange

Financial Results Announcement

Annual Meeting and Liabilit...

Financial Results Announcement

Appointment of Directors

Earnings Reports

Private Placement

FDA Designation for TYRA-30...

Initiation of SURF201 Phase...

Earnings Reports

Amended and Restated Bylaws

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Incentive Plan Adoption and...

External Links:

On August 21, 2025, Tyra Biosciences, Inc. announced the first child enrollment in their BEACH301 Phase 2 study of dabogratinib for treating achondroplasia, with initial safety results expected in late 2026.

AI Assistant

TYRA BIOSCIENCES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.